Shandong Xinhua Pharmaceutical Co. Ltd. provided earnings guidance for the period from 1 January 2015 to 31 December 2015. For the period, the group is expected to record an increase in the net profit attributable to the Shareholders as compared to the corresponding period in 2014.

Net profit attributable to the shareholders is expected to be between RMB 76,087,500 to RMB 91,305,000, representing an approximate increase of 50%-80% as compared with that during the corresponding period of last year. Basic earnings per share to approximate RMB 0.17 to RMB 0.20. The expected increase in profit is mainly attributable to the following initiatives adopted by the Company: significant adjustment to the product structure achieving expansion in the sale scale of high value added products; in depth research on technology leading to reduction of energy and consumption; and continual price comparison policy in procurement process attaining reduction in production costs.